Research progress of immune checkpoint inhibitors related thyroid dysfunction

Du Jing; Ren Ziyu; Tian Mingyuan; Liu Dongfang

doi:10.13406/j.cnki.cyxb.003133

您当前的位置：

首页 >

文章列表页 >

Research progress of immune checkpoint inhibitors related thyroid dysfunction

The discussion on thyroid dysfunction | 更新时间：2025-10-21

- Research progress of immune checkpoint inhibitors related thyroid dysfunction
- Journal of Chongqing Medical University Vol. 47, Issue 11, Pages: 1311-1315(2022)
- 作者机构：
  
  重庆医科大学附属第二医院内分泌代谢科，重庆 400010
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003133
  CLC： R730.51;R581
- Received：19 April 2022，
  
  Published：28 November 2022
- 稿件说明：
移动端阅览
杜静,任子愚,田茗源,等.免疫检查点抑制剂相关甲状腺功能障碍研究进展[J].重庆医科大学学报,2022,47(11):1311-1315.

Du Jing,Ren Ziyu,Tian Mingyuan,et al.Research progress of immune checkpoint inhibitors related thyroid dysfunction[J].Journal of Chongqing Medical University,2022,47(11):1311-1315.
杜静,任子愚,田茗源,等.免疫检查点抑制剂相关甲状腺功能障碍研究进展[J].重庆医科大学学报,2022,47(11):1311-1315. DOI： 10.13406/j.cnki.cyxb.003133.

Du Jing,Ren Ziyu,Tian Mingyuan,et al.Research progress of immune checkpoint inhibitors related thyroid dysfunction[J].Journal of Chongqing Medical University,2022,47(11):1311-1315. DOI： 10.13406/j.cnki.cyxb.003133.

摘要

免疫检查点抑制剂（immune checkpoint inhibitors，ICPIS）对肿瘤患者总体生存率有极大提高，疗效显著，目前已批准用于多种肿瘤治疗，为众多癌症患者带来希望。但治疗同时，过度激活的免疫系统对全身各个器官均可产生免疫损伤，甲状腺功能障碍就是其中较为常见的内分泌不良事件之一。本文回顾相关文献，从ICPIS分布及作用特点、流行病学、发病机制出发，归纳总结其临床特点，并就临床工作中如何筛选高危患者，以及目前国内外指南关于ICPIS相关甲状腺功能障碍随访监测、治疗方式异同进行阐述。

Abstract

Immune checkpoint inhibitors（ICPIS） can greatly improve the overall survival rate of tumor patients with significant efficacy. Currently， ICPIS have been approved for a variety of tumor treatments， bringing hope to many cancer patients. However，at the same time， due to the overactivation of the immune system， it can produce immune-related adverse reactions to all organs of the body. Thyroid related dysfunction is one of the relatively common endocrine adverse events in the treatment of ICPIS. This paper reviewed relevant literature and summarized the clinical characteristics of ICPIS from the perspectives of distribution， action characteristics，epidemiology and pathogenesis. In addition， how to screen high-risk patients in clinical work， as well as the differences and similarities of follow-up monitoring and treatment methods of ICPIS-related thyroid dysfunction in current domestic and foreign guidelines are discussed.

关键词

Keywords

references

Kennedy LB ， Salama AKS . A review of cancer immunotherapy toxicity [J ] . CA Cancer J Clin ， 2020 ， 70 （ 2 ）： 86 - 104 .

杨　涛，赵家军 . 免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识（2020） [J ] . 中华内分泌代谢杂志， 2021 ， 37 （ 1 ）： 1 - 16 .

Yang T ， Zhao JJ . Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events（2020） [J ] . Chin J Endocrinol Metab ， 2021 ， 37 （ 1 ）： 1 - 16 .

Ostrov DA ， Shi W ， Schwartz JC ， et al . Structure of murine CTLA-4 and its role in modulating T cell responsiveness [J ] . Science ， 2000 ， 290 （ 5492 ）： 816 - 819 .

Waterhouse P ， Penninger JM ， Timms E ， et al . Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4 [J ] . Science ， 1995 ， 270 （ 5238 ）： 985 - 988 .

Postow MA ， Sidlow R ， Hellmann MD . Immune-related adverse events associated with immune checkpoint blockade [J ] . N Engl J Med ， 2018 ， 378 （ 2 ）： 158 - 168 .

Boussiotis VA . Molecular and biochemical aspects of the PD-1 checkpoint pathway [J ] . N Engl J Med ， 2016 ， 375 （ 18 ）： 1767 - 1778 .

Cheung YMM ， Wang W ， McGregor B ， et al . Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors：a systematic review and Meta-analysis [J ] . Cancer Immunol Immunother ， 2022 ， 71 （ 8 ）： 1795 - 1812 .

Barroso-Sousa R ， Barry WT ， Garrido-Castro AC ， et al . Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens：a systematic review and Meta-analysis [J ] . JAMA Oncol ， 2018 ， 4 （ 2 ）： 173 - 182 .

Zhai YH ， Ye XF ， Hu FY ， et al . Endocrine toxicity of immune checkpoint inhibitors：a real-world study leveraging US Food and Drug Administration adverse events reporting system [J ] . J Immunother Cancer ， 2019 ， 7 （ 1 ）： 286 .

Peiffert M ， Cugnet-Anceau C ， Dalle S ， et al . Graves' disease during immune checkpoint inhibitor therapy（a case series and literature review） [J ] . Cancers ， 2021 ， 13 （ 8 ）： 1944 .

Muir CA ， Clifton-Bligh RJ ， Long GV ， et al . Thyroid immune-related adverse events following immune checkpoint inhibitor treatment [J ] . J Clin Endocrinol Metab ， 2021 ， 106 （ 9 ）： e3704 - e3713 .

Delivanis DA ， Gustafson MP ， Bornschlegl S ， et al . Pembrolizumab-induced thyroiditis：comprehensive clinical review and insights into underlying involved mechanisms [J ] . J Clin Endocrinol Metab ， 2017 ， 102 （ 8 ）： 2770 - 2780 .

Angell TE ， Min L ， Wieczorek TJ ， et al . Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma [J ] . Genes Dis ， 2018 ， 5 （ 1 ）： 46 - 48 .

Jabkowski J ， Loidl A ， Auinger B ， et al . Pembrolizumab-induced thyroiditis shows PD-L1 expressing histiocytes and infiltrating T cells in thyroid tissue：a case report [J ] . Front Immunol ， 2021 ， 12 ： 606056 .

Kotwal A ， Gustafson MP ， Bornschlegl S ， et al . Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations [J ] . Thyroid ， 2020 ， 30 （ 10 ）： 1440 - 1450 .

Osorio JC ， Ni A ， Chaft JE ， et al . Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer [J ] . Ann Oncol ， 2017 ， 28 （ 3 ）： 583 - 589 .

Okada N ， Iwama S ， Okuji T ， et al . Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies：a prospective study [J ] . Br J Cancer ， 2020 ， 122 （ 6 ）： 771 - 777 .

de Moel EC ， Rozeman EA ， Kapiteijn EH ， et al . Autoantibody development under treatment with immune-checkpoint inhibitors [J ] . Cancer Immunol Res ， 2019 ， 7 （ 1 ）： 6 - 11 .

Muir CA ， Wood CCG ， Clifton-Bligh RJ ， et al . Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events [J ] . J Clin Endocrinol Metab ， 2022 ， 107 （ 5 ）： e1843 - e1849 .

Ryder M ， Callahan M ， Postow MA ， et al . Endocrine-related adverse events following ipilimumab in patients with advanced melanoma：a comprehensive retrospective review from a single institution [J ] . Endocr Relat Cancer ， 2014 ， 21 （ 2 ）： 371 - 381 .

Presotto EM ， Rastrelli G ， Desideri I ， et al . Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab：results of a large multicentre study [J ] . J Endocrinol Invest ， 2020 ， 43 （ 3 ）： 337 - 345 .

Zhang Y ， Garofano F ， Wu XL ， et al . Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics [J ] . Invest New Drugs ， 2020 ， 38 （ 6 ）： 1717 - 1729 .

Pollack R ， Ashash A ， Cahn A ， et al . Immune checkpoint inhibitor-induced thyroid dysfunction is associated with higher body mass index [J ] . J Clin Endocrinol Metab ， 2020 ， 105 （ 10 ）： e3620 - e3627 .

Kim W ， Cho YA ， Kim DC ， et al . Factors associated with thyroid-related adverse events in patients receiving PD-1 or PD-L1 inhibitors using machine learning models [J ] . Cancers ， 2021 ， 13 （ 21 ）： 5465 .

Hribernik N ， Huff DT ， Studen A ， et al . Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients：a pilot study [J ] . Eur J Nucl Med Mol Imaging ， 2022 ， 49 （ 6 ）： 1857 - 1869 .

Chiloiro S ， Bianchi A ， Giampietro A ， et al . The changing clinical spectrum of endocrine adverse events in cancer immunotherapy [J ] . Trends Endocrinol Metab ， 2022 ， 33 （ 2 ）： 87 - 104 .

Haanen JBAG ， Carbonnel F ， Robert C ， et al . Management of toxicities from immunotherapy：ESMO clinical practice guidelines for diagnosis，treatment and follow-up [J ] . Ann Oncol ， 2017 ， 28 （ Suppl 4 ）： iv119 - iv142 .

Zhan L ， Feng HF ， Liu HQ ， et al . Immune checkpoint inhibitors-related thyroid dysfunction：epidemiology，clinical presentation，possible pathogenesis，and management [J ] . Front Endocrinol（Lausanne）， 2021 ， 12 ： 649863 .

Brahmer JR ， Lacchetti C ， Schneider BJ ， et al . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy：American society of clinical oncology clinical practice guideline [J ] . J Clin Oncol ， 2018 ， 36 （ 17 ）： 1714 - 1768 .

Thompson JA . New NCCN guidelines：recognition and management of immunotherapy-related toxicity [J ] . J Natl Compr Canc Netw ， 2018 ， 16 （ 5S ）： 594 - 596 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Association between thyroid dysfunction and venous thrombosis： a two-sample bidirectional Mendelian randomization study

Causality between thyroid dysfunction and lacunar stroke： a bidirectional，two-sample Mendelian randomization study

Causal relationship between thyroid dysfunction and prostate cancer： a two-sample Mendelian randomization study

Immunotherapy: a promising therapy for anaplastic thyroid carcinoma

Chinese expert consensus on immune checkpoint inhibitors induced emergency management of endocrine adverse reactions

Related Author

Jiang Chuli

Tian Hao

He Linxiang

Zhang Wei

Zhao Yu

Lü Xiaofeng

Liang Jingtao

Deng Xinmin

Related Institution

Department of Vascular Surgery，The First Affiliated Hospital of Chongqing Medical University

School of Clinical Medicine，Chengdu University of Traditional Chinese Medicine

Department of Neurology， Affiliated Hospital of Chengdu University of Traditional Chinese Medicine

The Second Clinical College of Guangzhou University of Chinese Medicine

Department of Urology， Guangdong Provincial Hospital of Chinese Medicine

⁰